Claim · claimSorter/cs-057

The ethnobotanical pharmacopoeia represents the most important untapped resource for new drug development

Education, not medical advice. Drafts and study material from an independent research library. Citations on this page were checked on Oct 13, 2026; claims in the body text and organizational sources are still under review. What was checked.

The ethnobotanical pharmacopoeia represents the most important untapped resource for new drug development

Unresolved recorded as “A Judgment, Not a Testable Finding” Plants of the Gods

Newman & Cragg (Journal of Natural Products, 2020): 50% of drugs approved 1981-2019 were natural product-derived or inspired. Fabricant & Farnsworth (Environmental Health Perspectives, 2001) reported that most plant-derived drugs they reviewed are used in ways related to their traditional uses; a '30x more efficient' figure often attached to them could not be found in the paper (Source not found; under review). Schultes's 91 plants have produced: psilocybin (in Phase 3 trials), ibogaine (early studies), mescaline (decriminalized in Colorado), DMT and ayahuasca (early trials), multiple non-psychedelic therapeutic leads. The pharmacological resource Schultes documented is far from exhausted.